Pilot study of combined blockade of the renin-angiotensin system in essential hypertensive patients

Journal of Hypertension

Volumn 18, Issue 8, 2000, Pages 1139-1147

  Azizi, Michel ^a   Linhart, Ales ^a   Alexander, Joe ^b   Goldberg, Allan ^b   Menten, Joris ^b   Sweet, Charles ^b   Ménard, Joël ^a  

^a HÔPITAL BROUSSAIS   (France)

^b MERCK RESEARCH LABORATORIES   (United States)

Author keywords

ACE inhibitor; Angiotensin II antagonist; Combination therapy; Essential hypertension

Indexed keywords

ANGIOTENSIN II ANTAGONIST; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ENALAPRIL; LOSARTAN; PLACEBO;

ADULT; AGED; ARTICLE; BLOOD PRESSURE MEASUREMENT; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIASTOLIC BLOOD PRESSURE; DOUBLE BLIND PROCEDURE; ESSENTIAL HYPERTENSION; FEMALE; HUMAN; HYPERTENSION; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; TREATMENT OUTCOME;

EID: 0033863437     PISSN: 02636352     EISSN: None     Source Type: Journal    
DOI: 10.1097/00004872-200018080-00020     Document Type: Article

References (25)

1. Combined renin and converting enzyme inhibition in rats
2. Investigation of the biochemical effects of renin inhibition in normal volunteers treated by an ACE inhibitor
3. Synergistic effect on reduction in blood pressure with coadministration of a renin inhibitor or an angiotensin-converting enzyme inhibitor with an angiotensin II receptor antagonist
4. Additive effects of combined angiotensin-converting enzyme inhibition and angiotensin II antagonism on blood pressure and renin release in sodium-depleted normotensives
5. Determinants of angiotensin II generation during converting enzyme inhibition
6. Evidence for a putatively new angiotensin II-generating enzyme in the vascular wall
7. Identification of a highly specific chymase as the major angiotensin II-forming enzyme in the human heart
8. Effect of bradykinin-receptor blockade on the response to angiotensin-converting-enzyme inhibitor in normotensive and hypertensive subjects
9. Additive effects of losartan and enalapril on blood pressure and plasma active renin
10. Synergistic effects of ACE inhibition and Ang II antagonism on blood pressure, cardiac weight and renin in spontaneously hypertensive rats
11. Synergistic effects of combined converting enzyme inhibition and angiotensin II antagonism on blood pressure in conscious telemetered spontaneously hypertensive rats
12. Enalapril and losartan reduced cardiac mass and improved coronary hemodynamics in SHR
13. Additive effects of enalapril and losartan in (mREN-2)27 transgenic rats
14. Modulation of the renin-angiotensin pathway through enzyme inhibition and specific receptor blockade in pacing-induced heart failure: II. Effects on myocyte contractile processes
15. Augmented short- and long-term hemodynamic and hormonal effects of an angiotensin receptor blocker added to angiotensin converting enzyme inhibitor therapy in patients with heart failure
16. Addition of angiotensin II receptor blockade to maximal angiotensin-converting enzyme inhibition improves exercise capacity in patients with severe congestive heart failure
17. Combination ACE inhibitor and angiotensin II receptor antagonist therapy in diabetic nephropathy
18. Spectrophotometric assay and properties of the angiotensin-converting enzyme of rabbit lung
19. Measurement of converting enzyme activity by antibody-trapping of generated angiotensin II
20. High plasma level of acetyl-seryl-aspartyl-lysyl-proline: A new marker of chronic angiotensin-converting enzyme inhibition
21. Pharmacokinetics in healthy volunteers and patients of NA(c)-SDKP (Seraspenide), a negative regulator of hematopoiesis
22. Multiple testing in clinical trials
23. Vasoconstriction-volume analysis for understanding and treating hypertension. The use of renin and aldosterone profiles
24. The dose-response relationship with angiotensin converting enzyme inhibitors: Effects on blood pressure and biochemical parameters
25. International Society of Hypertension Guidelines for the Management of Hypertension Guidelines Subcommittee